06/14/2002 By Elda Hauschildt
Capecitabine therapy for progressive metastatic cholangiocarcinoma was well tolerated and did not result in severe side effects in a preliminary study of two patients. Researchers, from the University Clinic in Munich, Germany, observed that disease progression stopped and suggest that capecitabine is a potential second-line treatment for these patients.
The investigators say management of recurrent, metastatic cholangiocarcinoma is a problem because the tumour is classified as chemotherapy-resistant.
This means palliation is the main therapeutic goal when advanced or metastatic disease is diagnosed.
Both study participants had previously received chemotherapy, including hepatic artery infusion of 5-fluorouracil (5-FU)/folinic acid and oxaliplatin and a combination of 5-FU/FA and gemcitabine.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!